PHARMA MAR, S.A. «12345...» Página 3 de 18 desde 01/07/1988 hasta 14/05/2024 12/06/2019 17:45 PHARMA MAR, S.A. Employees share and stock ownership schemes The Executive Committee of Pharma Mar, S.A. has decided to implement the Free of Charge Stock Ownership Plan approved by resolution of the Annual General Shareholders´ Meeting of 28 June 2018. Número de registro: 279065 03/06/2019 09:31 PHARMA MAR, S.A. Announcements of public presentations and meetings Conference call related to the Zepsyre results recently presented at ASCO by Dr. Paz Ares. Número de registro: 278779 Relacionado con 278775 del 01/06/2019 (22:48) 01/06/2019 22:48 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks Information about the results presented at the annual meeting of the American Society of Clinical Oncology (ASCO) concerning Zepsyre Número de registro: 278775 Relacionado con 278282 del 16/05/2019 (07:37) 23/05/2019 15:16 PHARMA MAR, S.A. Announcements and resolutions of general shareholders meetings. - Composition of the board of directors The Company announces decision of the Board of Directors to call the Ordinary General Shareholders´ Meeting on 25/06/2019 and 26/06/2019, respectively, on the first and second call notice. The Company sends notice of call and proposed resolutions Número de registro: 278507 23/05/2019 14:49 PHARMA MAR, S.A. Transmissions and purchases of capital undertakings The Board of Directors of Pharma Mar has approved the signing of a contract for the sale of the shares of its subsidiary Zelnova Zeltia, subject to the approval of the General Shareholders Meeting. Número de registro: 278505 Relacionado con 274204 del 28/01/2019 (19:45) 16/05/2019 07:37 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks Abstract information to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) concerning Lurbinectedin Número de registro: 278282 Relacionado con 276625 del 01/04/2019 (08:18) 15/05/2019 07:36 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks American Society of Clinical Oncology (ASCO) selects a lurbinectedin abstract for “Best of ASCO” program. Número de registro: 278266 26/04/2019 18:37 PHARMA MAR, S.A. Credit ratings Axesor ratifies the rating of Pharma Mar, S.A. and its outlook as stable. Número de registro: 277498 26/04/2019 18:30 PHARMA MAR, S.A. Information on P&L The Company sends press release regarding the Q1 2019 results Número de registro: 277497 26/04/2019 18:19 PHARMA MAR, S.A. Interim financial information La sociedad remite información sobre los resultados del primer trimestre de 2019 Número de registro: 277496 Página 3 de 18 «12345...»
